Introduction

Myelodysplastic syndromes (MDS) are defined in the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues as a group of clonal hematopoietic stem cell diseases characterized by cytopenia, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, and increased risk of progression to acute myeloid leukemia (AML).1
Source: Seminars in Hematology - Category: Hematology Authors: Source Type: research